DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Capmatinib works in patients with lung cancer with a particular mutation in their cancer known as a METex14 skipping mutation. Investigators now wish to find out if it will be useful in treating patients with other cancer types which have the same mutation or other specific mutations or changes which take place in the MET gene. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future. This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.

NCT Number	NCT06988475
Lead Sponsor	Cancer Research UK Collaborators: University of Birmingham, Royal Marsden NHS Foundation Trust, Novartis Pharmaceuticals, University of Manchester
Conditions	Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Malignancy, Glioma +3 more
Enrollment	30 participants
Start Date	2024-11-19
Primary Completion	2029-10 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2025-11-24